key: cord-0891754-rzv2h3r9 authors: Lopes, Desirée V.; Lazar Neto, Felippe; Marques, Lais C.; Lima, Rodrigo B.O.; Brandão, Antonio Adolfo Guerra Soares title: Methemoglobinemia and Hemolytic Anemia after COVID-19 Infection Without Identifiable Eliciting Drug: A Case-Report date: 2020-11-19 journal: IDCases DOI: 10.1016/j.idcr.2020.e01013 sha: 811903a8013e011a555cefc2bb15daf06adea0b3 doc_id: 891754 cord_uid: rzv2h3r9 We report a second case of methemoglobinemia and non-autoimmune hemolytic anemia after contracting the SARS-CoV-2 infection in the absence of an identifiable eliciting drug. A 35-year old male without previous known comorbidities was admitted after he was diagnosed with the COVID-19 infection and had large pulmonary involvement. Seven days later, he desaturated but was without any signs of respiratory distress. A check of arterial blood gas revealed normal partial pressure of oxygen and follow-up tests confirmed a methemoglobinemia diagnosis. Over the next few days, hemolysis was established after decreased levels of hemoglobin and increased levels of indirect bilirubin and lactate dehydrogenase. A hemolytic anemia investigation panel came back normal, including G6PD. A second G6PD test was ordered at the 5-month follow-up appointment and revealed decreased levels. Clinicians should thus be aware of possible false negative tests when testing for G6PD during hemolytic crisis. In addition, whether the COVID-19 infection alone would be responsible for this chain of events remains a challenging question. COVID-19 is an emerging infectious disease caused by the SARS-CoV-2 virus that has infected more than 50 million people worldwide [1] . Although most patients will have mild limited symptoms, 5% of them will develop severe acute distress syndrome and need advanced care [2] . In addition to respiratory involvement, thrombotic complications are well described after infection [3] . A possible explanation include the activation of cytokines, ultimately leading to vascular damage and activation of the coagulation cascade [4] . Conversely, there are few cases of hemolysis described in the medical literature. A seven patient case-series reported both warm and cold anti-erythrocyte antibodies mediated hemolysis in COVID-19 infected patients [5] . Methemoglobinemia, also uncommon, has been described mostly after hydroxychloroquine administration [6] . Only one case-report has shown both hemolysis and methemoglobinemia without any known eliciting drug in a COVID-19 infected patient with a G6PD deficiency [7] . Here we report a second case of both concurrent conditions following infection. A 35-year old man presented to the emergency department with a 5 day history of abdominal pain and nausea, and a 2 day history of subjective fevers and diarrhea. He denied any upper or lower respiratory symptoms. His initial vital signs included a blood pressure of 110/90mmHg, heart rate of 78, temperature of 36 degrees Celsius and respiratory rate of 20. His peripheral oximetry showed a 93% saturation on room air. Physical exam was unremarkable, white any signs of respiratory distress. Initial J o u r n a l P r e -p r o o f laboratory exams showed a slight elevation in hepatic transaminases, lymphopenia and altered c-reactive protein (Table 1) . A chest x-ray revealed bilateral infiltrates and chest tomography demonstrated multiple ground glass opacities involving 50% of lung fields. Although the patient denied any suspicious COVID-19 contact, a rt-PCR from nasopharyngeal swab was ordered and confirmed the infection. He was then sent to the inpatient unit and started on antibiotics according to hospital protocol (seven and fiveday administration of ceftriaxone and azithromycin respectively). Seven days later, the patient desaturated to 78% on room air, still without any signs of respiratory distress or dyspnea complaints. He was pale (2+/4+), icteric (+/4+) and with brown-colored urine at physical examination. He was then placed on a nonrebreather mask (7 liters/minute) but remained hypoxemic -82%. An arterial blood gas (ABG) while in oxygen therapy showed pH of 7.42, pCO2 of 46mmHg, pO2 of 167mmHg and oxygen saturation of 100%. Methemoglobin ordered the next day was found to be at 10.5%. In addition, blood count revealed new anemia with 8. The patient progressed with worsening anemia and renal dysfunction in the following days but without need for renal replacement therapy. He had a minimum hemoglobin of 5 g/dL and a maximum creatinine of 6.8 g/dL during hospitalization. His peripheral oxygen saturation continued to be lower than observed at the ABG over the next 3 days. He received two packed red blood cells while in UCI. After three days, laboratory evidence of hemolysis diminished and the patient clinically improved. He is sent back to the inpatient unit on the 14th day of hospitalization and is discharged home 7 days later. His pre-discharge medical exams showed a hemoglobin of 7.6 g/dL and creatinine of 3.9 g/dL. At the 2 month follow-up in the outpatient clinic, he did not have any complaints and his laboratory panel revealed hemoglobin of 10.5 g/dL and improved renal function with a creatinine of 1.5 g/dL. A new G6PD dosage ordered after 5 months revealed decreased levels (3.78 U/g/Hb) and therefore confirmed the diagnosis of G6PD deficiency. Methemoglobinemia is an uncommon condition characterized by tissue hypoxia with normal partial pressure of oxygen in the blood [8] . Patients typically present with cyanosis and dyspnea that, in rare cases, progress to coma, shock or severe respiratory failure due to hypoxia [9] . This is caused by the oxidation of hemoglobin's iron to its ferric state, which leads to a failure of oxygen carriage by the hemoglobin. In its acquired form, toxins and medications are the major triggers of the oxidation burst. Because of its pathophysiology, patients with anti-oxidation genetic defects are more prone to this condition [8] . The concurrence of methemoglobinemia and non-immune hemolytic anemia has been well-documented in patients with an inherited G6PD defect and/or the overdose of a known oxidative medication. The proposed mechanism involves the production of excess reactive oxygen species (ROS) leading to both iron oxidation and hemolysis. If G6PD is low, reduced glutathione is rapidly depleted, and even small oxidative insults can cause irreversible damage [10] . Conversely, when G6PD levels are normal, the insult must be high enough to saturate cell oxidation reduction capacity and damage red blood cells. This is commonly observed after an overdose of highly oxidative medications such as dapsone [11] . Oxidative stress damage plays also an important role in infections. For instance, influenza perhaps promotes most lung cell injury through excessive production of ROS derivatives [12] . However, whether infection-related ROS insults are enough to promote both methemoglobin and hemolysis is still unknown. Researchers reported the above co-occurrence after campylobacter enteritis [13] and hepatitis E virus infection [14] . With respect to COVID-19, there is increasing evidence that oxidative stress worsens lung J o u r n a l P r e -p r o o f injury during infection: an imbalance of high ROS production and weak anti-oxidation system is thought to explain disease progression and severity in preclinical studies [15] . A recent report described the concurrence of hemolysis and methemoglobinemia in a COVID-19 infected patient with a G6PD deficiency [7] . Here we report a second case of both conditions in a patient with the same inherited defect. Interestingly, G6PD was within normal ranges in the first dosage. A plausible explanation is the effect of reticulocytosis on plasma levels [16] . Importantly, in both reports, no medication trigger was found. Whether the COVID-19 infection alone is responsible for this chain of events remains a challenging question. Our case expands on this topic by presenting the second case of hemolysis and methemoglobinemia co-occurrence in a patient with G6PD deficiency without previous use of a clear eliciting drug. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. DVL collected the data. DVL, LCM and FLN wrote the manuscript with the supervision of RBOL and AAGSB. All authors helped shape the manuscript. All authors provided critical feedback and helped shape the research, interpretation and manuscript. J o u r n a l P r e -p r o o f COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation Pediatr Blood Cancer A Systematic Review of Cases of Acute Respiratory Distress Syndrome in the Coronavirus Disease Incidence of thrombotic complications in critically ill ICU patients with COVID-19 COVID-19: consider cytokine storm syndromes and immunosuppression Autoimmune haemolytic anaemia associated with COVID-19 infection The emergence of methemoglobinemia amidst the COVID-19 pandemic Methemoglobinemia in Patient with G6PD Deficiency and SARS-CoV-2 Infection Concise review: methemoglobinemia Methemoglobinemia: a review and recommendations for management Severe hemolysis and methemoglobinemia following fava beans ingestion in glucose-6-phosphatase dehydrogenase deficiency: case report and literature review Incidence and patterns of hemolytic anemia in acute dapsone overdose The role of oxidative stress in influenza virus infection Methemoglobinemia and hemolytic anemia associated with Campylobacter jejuni enteritis Hemolysis and methemoglobinemia due to hepatitis E virus infection in patient with G6PD deficiency Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection G6PD deficiency: a classic example of pharmacogenetics with ongoing clinical implications The patient consented with the publication of this manuscript.